News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

OctoPlus Wins Drug Manufacturing Contract From Existing Client



11/22/2011 7:37:27 AM

LEIDEN, NETHERLANDS--(Marketwire - November 22, 2011) - OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), announces today that it has received a commitment from an existing client for OctoPlus to manufacture additional drug product for this client. The contract value will make a material contribution to OctoPlus' annual revenues in 2012. Further financial details are not disclosed.

At OctoPlus we provide formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. In addition to our expertise in formulation and manufacturing, we offer our clients drug delivery technologies for the development of controlled release versions of existing or new drugs.

About OctoPlus
OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on our proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics.

The clinically most advanced product incorporating our technology is Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and has completed Phase IIb clinical studies with superior clinical data versus current treatment.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

This document may contain certain forward-looking statements relating to the business, financial performance and results of the Company and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

Click here for the press release in PDF format
http://hugin.info/137076/R/1565544/485917.pdf


For further information, please contact:
Rianne Roukema
Corporate Communications
telephone number +31 (71) 524 1071
e-mail: IR@octoplus.nl


Read at BioSpace.com


comments powered by Disqus
OctoPlus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES